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Abstract: Citrullination, a posttranslational modification, is catalyzed by peptidylarginine deiminases
(PADs), a unique family of enzymes that converts peptidyl-arginine to peptidyl-citrulline.
Overexpression and/or increased PAD activity is observed in rheumatoid arthritis (RA), Alzheimer’s
disease, multiple sclerosis, and cancer. Moreover, bacterial PADs, such as Porphyromonas gingivalis
PAD (PPAD), may have a role in the pathogenesis of RA, indicating PADs as promising therapeutic
targets. Herein, six novel compounds were examined as potential inhibitors of human PAD4 and
PPAD, and compared to an irreversible PAD inhibitor, Cl-amidine. Four of the tested compounds
(compounds 2, 3, 4, and 6) exhibited a micromolar-range inhibition potency against PAD4 and no effect
against PPAD in the in vitro assays. Compound 4 was able to inhibit the PAD4-induced citrullination
of H3 histone with higher efficiency than Cl-amidine. In conclusion, compound 4 was highly effective
and presents a promising direction in the search for novel RA treatment strategies.
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1. Introduction
Citrullination is a post-translational modification of protein-bound arginine into the nonstandard
amino acid, citrulline, catalyzed by Ca2+-dependent peptidylarginine deiminase (PAD) enzymes [1].
The citrullination process significantly alters the structure, stability and function of proteins and,
as such, may affect numerous physiological and pathological processes, including gene expression,
inflammation, or even the facilitation of metastasis [2–4]. To date, five isoforms of this enzyme have
been identified (PAD1 to 4 and PAD6) with different tissue expression patterns and consequently
different functions [5]. PAD-induced citrullination has been studied in different physiological and
pathological conditions. PAD1, physiologically implicated in the keratinization of the skin, has been
demonstrated to be hypofunctional in psoriasis; on the other hand, PAD2, essential for myelin sheath
stability and the plasticity of the brain, is hyperfunctional in multiple sclerosis. PAD4, the most
prominent among PADs, plays a role in tumorigenesis by influencing the expression of p53 target
genes and is strongly implicated in the pathogenesis of atherosclerosis by modulating of the function of
chemokines, antibacterial neutrophil extracellular traps (NETs) formation and in the generation of new
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autoantigens in rheumatoid arthritis (RA) [5]. Autoantibodies against citrullinated proteins (ACPAs)
are detectable in about 70% of patients with RA, can be present years before the clinical onset and
became an important prognostic biomarker [6]. As citrullinated proteins are highly specific targets of
the immune response in RA, it had been suggested that dysregulated PAD activity is a hallmark of the
immune tolerance breach driving the autoimmunity in RA. Indeed, both PAD2 and PAD4 are detected
in RA synovium and are closely associated with neutrophil infiltration of synovial tissues and the
intensity of inflammation [7]. Curiously, PAD4 polymorphism is associated with RA susceptibility in
Asian and North American populations [8–10], further strengthening its relevance to the pathogenesis
of this disease.
Moreover, PAD4 activity links citrullination, inflammation and autoimmunity by its role in the
formation of neutrophil extracellular traps (NETs). During a type of cell death, known as NETosis,
neutrophils release a highly decondensed chromatin meshwork of DNA, histones and a number of other
various proteins and peptides [11] that are typically present within the neutrophil granules. Although
considered a host defense mechanism, excessive NET formation contributes to the development of
many noninfectious diseases, including RA, systemic lupus erythematous, diabetes, atherosclerosis,
sepsis, thrombosis and even cancer [12]. PAD4 is essential for the formation of NETs by promoting
chromatin decondensation through histone citrullination [13,14], mainly H3 [15,16]. Enhanced NETosis
was observed in neutrophils isolated from blood and synovial fluid of patients with RA, when compared
to the neutrophils from healthy controls [17]. Moreover, citrullinated histones H2A, H2B [18], H3 [19],
and H4 [20] have been described as targets of ACPA antibodies generated by patients with RA.
In addition to the human PAD2 and PAD4, evidence suggests that bacterial PAD also may play a
role in the pathogenesis of RA. Among prokaryotes several pathogenic Porphyromonas species, including
Porphyromonas gingivalis, produce peptidylarginine deiminase (PPAD), that in contrast to mammalian
PADs, predominantly deiminates C-terminal arginine in both bacterial and host proteins [21,22], thus
generating novel citrullinated epitopes. P. gingivalis is considered a keystone pathogen in periodontitis,
a disease similar to RA which is characterized by chronic self-sustaining inflammation [23]. The PPAD
activity of this species could be responsible for the clinical association observed between RA and
periodontitis [24]. Hence, both human PADs and their bacterial counterpart may present a possible
therapeutic target in the treatment of RA.
Given the fundamental role PAD4 has in the transcriptional regulation and RA pathogenesis,
plenty of research and development work has attempted to develop PAD4 inhibitors to regulate
PAD4 activity and facilitate RA regression [25–27]. In recent years, several PAD inhibitors have been
described, but most of these compounds are relatively inefficient [28,29]. For now, the most effective
inhibitors are the irreversible haloacetamidine compounds, e.g., F- and Cl-amidine, with IC50 ranging
from 1.9 to 22 µM [26]. Both F- and Cl-amidine have been shown to be active against PAD4 in vitro and
in vivo [25,26]. Cl-amidine has been shown to reduce clinical signs and symptoms of colitis [30] and a
decrease in the severity of murine collagen-induced arthritis (CIA) [31]. One of the second generation
PAD inhibitors, BB-Cl-amidine, ameliorates the severity of joint inflammation in CIA mice through
modulation of the T-cell immune responses [32]. Additionally, Wang and co-workers developed
compound YW3-56, a Cl-amidine analog with improved bioavailability [33]. This compound was able
to alter SESN2 which encodes an upstream inhibitor of the mammalian target of rapamycin complex 1
(mTORC1) signaling pathway, illustrating its potential to target anticancer reagents [33]. Most of the
reversible inhibitors including taxol, streptomycin and minocycline are relatively weak with millimolar
IC50 values [25], except GSK199 and GSK484 [14], the first highly potent PAD4-specific inhibitors with
IC50 of 0.2 and 0.05 µM. Although the number of available PAD4 inhibitors increased dramatically
in recently years, they are still far from a mechanism-based drug for PAD4. Therefore, developing
novel and highly potent PAD4-specific inhibitors is crucial. In this study, six novel compounds were
examined as potential PAD4 and PPAD inhibitors in comparison to the widely used irreversible
inhibitor, Cl-amidine.
Int. J. Mol. Sci. 2019, 20, 2174 3 of 16
2. Results
2.1. GST-PAD4 and HisTag-PPAD Kinetics
The kinetic parameters of the arginine-citrulline conversion were determined by the measurement
of the conversion rate in the series of increasing Dansyl-Gly-Arg substrate concentrations. Reaction
products were separated by HPLC and the resulting chromatograms were analyzed by peak integration
and standard curve calculation. The data was fit to the Michaelis-Menten equation and resulted in the
Km of 290 and 14 µM and kcat 0.46 and 0.81 s−1 for GST-PAD4 and HisTag-PPAD, respectively (Figure 1).
Calculated kcat values are based on the protein concentration in the sample, not on the enzyme titration
and, as such, should be regarded as the minimal values, assuming fully active enzymes. The kcat/Km
estimates are 1.5× 103 for GST-PAD4 and 5.7× 104 for HisTag-PPAD, corresponding with the previously
described substrate preference of these enzymes [21,34].
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PPAD), as well as the fitted model (curves) are shown. Results are expressed as mean ± SD, with n = 
3. 
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compounds 2, 3, 4, and 6, while no inhibition by compounds 1 and 5 was observed. No inhibition of 
HisTag-PPAD was observed for any of the tested inhibitors. Further, the inhibition assay was 
repeated at the lower concentrations of reducing agent in the assay buffer (DTT 0–10 mM, data not 
shown) and increased potential of compounds 2, 3, 4, and 6 was noted. The optimal inhibition was 
observed for the 0.5 mM DTT concentration (data not shown) and these conditions were chosen for 
the subsequent experiments. The values of Ki and IC50 for the tested compounds were determined in 
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indicate a good affinity of the compounds 2, 3, 4, and 6 to the GST-PAD4, in the low μM range for all 
compounds when tested in the optimized in vitro conditions, and the 50 μM concentration was 
chosen for subsequent experiments. However, compounds 1 and 5 exhibited no effect on the 
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Figure 1. Michaelis–Menten enzyme kinetics for GST-PAD4 (A) and HisTag-PPAD (B). The rate of
enzymatic product formation was plotted against the initial substrate concentration. Reaction rates
were determined by incubating GST-PAD4 or PPAD with increasing concentrations of Dansyl-Gly-Arg
in the presence of 10 mM CaCl2 and 10 mM DTT for 60 min prior to product separation by HPLC.
Amount of the product formation was calculated based on the product peak integration, compared to
the calibration curve. Experimental data (circles, GST-PAD; squares, PPAD), as well as the fitted model
(curves) are shown. Results are expressed as mean ± SD, with n = 3.
2.2. Analysis of GST-PAD4 and HisTag-PPAD Inhibition by Compounds 1–6
Initial screening of the compounds 1–6 was performed in the range of 0–250 µM inhibitor and
constant 0.25 mM Dansyl-Gly-Arg substrate concentrations. GST-PAD4 was partially inhibited by
compounds 2, 3, 4, and 6, while no inhibition by compounds 1 and 5 was observed. No inhibition of
HisTag-PPAD was observed for any of the tested inhibitors. Further, the inhibition assay was repeated
at the lower concentrations of reducing agent in the assay buffer (DTT 0–10 mM, data not shown) and
increased potential of compounds 2, 3, 4, and 6 was noted. The optimal inhibition was observed for
the 0.5 mM DTT concentration (data not shown) and these conditions were chosen for the subsequent
experiments. The values of Ki and IC50 for the tested compounds were determined in the series of
inhibitor concentrations (Table 1). Ki were determined by the nonlinear fit of the Morrison equation
to the experimental data from the range of inhibitor concentrations, while IC50 was defined as the
inhibitor concentration at which reaction rate reaches 50% of the maximum and determined by the
linear regression for each inhibitor (Figure 2). The determined parameters indicate a good affinity
of the compounds 2, 3, 4, and 6 to the GST-PAD4, in the low µM range for all compounds when
tested in the optimized in vitro conditions, and the 50 µM concentration was chosen for subsequent
experiments. However, compounds 1 and 5 exhibited no effect on the GST-PAD4 activity, and were
therefore excluded from further study.
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Table 1. Ki and IC50 values of candidate compounds.
Compound Ki (µM) a IC50 (µM)
1 b - -
2 0.94 ± 0.31 1.40 ± 0.26
3 0.71 ± 0.17 1.65 ± 1.34
4 1.00 ± 0.16 1.88 ± 0.26
5 b - -
6 0.61 ± 0.12 1.28 ± 0.30
Values were determined by the equilibrium-state experiment, where GST-PAD4 was preincubated with the indicated
compound prior to the substrate addition. The equilibrium inhibition constant (Ki) for each compound was obtained
from global fit to the tight-binding inhibition equations. IC50 was determined as the concentration of the inhibitor
that yields half-maximal activity, as determined by linear regression. Values are mean ± S.D. with n = 3. a Assuming
competitive reversible mechanism of inhibition. b No inhibition was observed at concentrations up to 250 µM.
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 16 
 
Table 1. Ki and IC50 values of candidate compounds. 
Compound Ki (μM) a IC50 (μM) 
1 b - - 
2 0.94 ± 0.31 1.40 ± 0.26 
3 0.71 ± 0.17 1.65 ± 1.34 
4 1.00 ± 0.16 1.88 ± 0.26 
5 b - - 
6 0.61 ± 0.12 1.28 ± 0.30 
Values were determined by the equilibrium-state experiment, where GST-PAD4 was preincubated 
with the indicated compound prior to the substrate addition. The equilibrium inhibition constant (Ki) 
for each compound was obtained from global fit to the tight-binding inhibition equations. IC50 was 
determined as t e concentratio  of the inhibitor that yields half-maximal activity, as determi ed by 
linear regression. Values are mean ± S.D. with n = 3. a Assuming competitive reversible mechanis  of 
inhibition. b No inhibition was observed at concentrations up to 250 μM. 
 
Figure 2. Inhibition of GST-PAD4 citrullination activity by compound 2 (A), 3 (B), 4 (C), and 6 (D). 
The residual activity of GST-PAD4 was plotted against the inhibitor compound concentration. 
Reaction rates were determined by pre-incubating GST-PAD4 and each compound in the presence of 
10 mM CaCl2 and 0.5 mM DTT for 30 min prior to the addition of 0.25 mM Dansyl-Gly-Arg to initiate 
the enzyme assay. Individual samples were analyzed by HPLC and product amount was estimated 
based on the peak area and compared to the GST-PAD4-released product in the same reaction buffer 
in the absence of the compounds. Experimental data (circles, compound 2; squares, compound 3; 
triangles, compound 4, and diamonds, compound 6) as well as the fitted model (curves) are shown. 
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interacting proteins, calcium concentrations and the reducing potential in the disease-affected areas, 
Figure 2. Inhibition of ST-P 4 citrullination activity by co pound 2 ( ), 3 (B), 4 ( ), and 6 ( ).
The residual activity of GST-PAD4 was plotted against the inhibitor compound concentration. Reaction
rates were determined by pre-incubating GST-PAD4 and each compound in the presence of 10 mM
CaCl2 and 0.5 mM DTT for 30 min prior to the addition of 0.25 mM Dansyl-Gly-Arg to initiate the
enzyme assay. Individual samples were analyzed by HPLC and product amount was estimated based
on the peak area and compared to the GST-PAD4-released product in the same reaction buffer in the
absence of the compounds. Experimental data (circles, compound 2; squares, compound 3; triangles,
compound 4, and diamonds, compound 6) as well as the fitted model (curves) are shown. Results are
expressed as mean ± SD, with n = 3.
Physiological conditions cannot be fully defined and controlled, especially regarding the interacting
proteins, calcium concentrations and the reducing potential in the disease-affected areas, therefore we
aimed to evaluate the compound potency in the samples collected from rheumatoid arthritis patients.
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First, the optimal serum dilution for GST-PAD4 activity in activity assay was determined. Serum
dilutions in the range 1:1.5–1:30 were tested. Results indicated that the highest GST-PAD4 activity
was achieved in the serum diluted four or more times, therefore, the 1:3 dilution was chosen for the
subsequent experiments. Next, the activity of the 50 µM inhibitory compounds on GST-PAD4 in the
presence of serum of healthy donors, as well as the serum and synovial fluid of patients with RA, all
diluted 1:3 in the assay buffer, was examined. The standard inhibitor, Cl-amidine, was employed as a
positive control in 50 and 200 µM concentration and compared to the tested compounds under the
same experimental conditions. The candidate molecules 1 and 5 did not show any detectable inhibitory
activity when tested in the presence of healthy controls or RA-patients serum, nor in patients synovial
fluid, indicating a significant loss of potential of these compounds in the in vivo-mimicking conditions
(Figure 3), whereas compound 3 retained weak inhibitory activity in the presence of serum from healthy
donors. Curiously, compounds 2, 4, and 6 retained their inhibitory potential in the presence of serum,
however it was diminished when compared to the in vitro conditions. No compound remained active
in the presence of RA synovial fluid. Interestingly, Cl-amidine, a standard, nonselective inhibitor of the
PAD family of enzymes, showed similar behavior, partially losing its inhibitory potential in the presence
of serum and becoming ineffective in the presence of RA synovial fluid. Notably, none of the inhibitors
reduced the GST-PAD4 activity by more than 60% in the presence of serum or synovial fluid (Figure 3).
Significantly, unlike all other compounds, inhibitory activity of compounds 4 and 6, although affected
by the presence of serum from healthy donors, did not diminish further in the presence of serum from
RA-patients, indicating improved stability of these compounds in in vivo-mimicking conditions when
compared to the Cl-amidine.
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Figure 3. Residual activity of GST-PAD4 after inhibition by candidate compounds and Cl-amidine
in the presence of serum from healthy blood donors, serum or synovial fluid from patients with RA.
GST-PAD4 was pre-incubated with DMSO alone, 50 µM of candidate compounds or 50 µM and 200 µM
of Cl-amidine in the presence of 10 mM CaCl2, 0.5 mM DTT and 1:3 diluted serum or synovial fluid for
30 min prior to the addition of 1 mM Dansyl-Gly-Arg to initiate the enzyme assay. Product generation
was evaluated by HPLC. Residual activity was determined in comparison to the respective GST-PAD4
control preincubated with DMSO alone. Black bars represent healthy serum, mid gray RA serum and
light grey RA synovial fluid, respectively. Results are expressed as mean ± SD, with n ≥ 3, and the
differences were considered significant if (*) p < 0.05 or (**) p ≤ 0.01.
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2.3. Inhibition of Histone H3 Citrullination and NET Formation
In order to follow the effect of the identified inhibitory compounds on the previously reported
biological activity of PAD4 [16], their ability to inhibit GST-PAD4-mediated citrullination of histone H3
was verified. Purified calf thymus histone H3 was incubated with GST-PAD4 in the presence of 50 µM
of the tested compounds, two concentrations of Cl-amidine, or in the absence of PAD4 inhibitors,
and the citrullination was evaluated by western blot (Figure 4A,C). Only compound 4 significantly
hampered the histone citrullination, inhibiting the reaction at 50 µM concentration, to the extent
comparable to 200 µM Cl-amidine, thus indicating its superior effectiveness. All other compounds and
50 µM Cl-amidine were not effective, as no significant change in the citrullinated histone H3-specific
band could be observed.
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Figure 4. Inhibition of histone H3 citrullination in vitro (A,C) and in isolated human neutrophils (B,D).
(A) GST-PAD4 was pre-incubated with DMSO alone, 50 µM of candidate compounds or 50 µM and
200 µM of Cl-amidine in the presence of 10 mM CaCl2 and 0.5 mM DTT for 30 min prior to the addition
of 5 µg of purified calf thymus histone H3 to initiate the enzyme assay. Following an incubation
period of 60 min, protein concentration was normalized and histones were analyzed by Western
blotting with an antibody against citrullinated histone H3. A representative blot of three experiments
is shown. Compounds 1 and 5 are not shown in the figure. (B) Human neutrophils, isolated from
healthy blood donors, were pre-incubated with DMSO alone, 50 µM of candidate compounds or 50
and 200 µM of Cl-amidine and then stimulated with 4 µM calcium ionophore. Total histones were
acid-extracted, protein concentration normalized and analyzed by Western blotting with an antibody
against citrullinated histone H3. Representative blots of three independent experiments are shown.
Band intensity was analyzed using ImageJ (freeware developed by NIH, Bethesda, USA) and values
were compared to the DMSO-only treated control with the Student t-test and the differences were
considered significant if (*) p < 0.05, (**) p ≤ 0.01 or (****) p ≤ 0.0001. Graphs represent inhibition of the
histone H3 citrullination in vitro (C) and in stimulated neutrophils (D).
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Histone H3 citrullination is an essential step in the neutrophil NETosis and is typically initiated by
the cytoplasm calcium influx stimulated by the external signaling pathways. Therefore, the peripheral
blood-isolated neutrophils were stimulated with calcium ionophore to induce Ca2+ downstream
effects. The histone H3 citrullination was evaluated by western blot, as described above, and the
inhibitory capability of compounds was estimated by comparing the band intensity to the ones resulting
from neutrophil incubation with Cl-amidine (50 and 200 µM) and to the DMSO-only vehicle sample.
Citrullination of histone H3 was visibly limited by 50 µM compound 4, with efficiency higher than
the 50 µM Cl-amidine, once more indicating the increased relative effectiveness of compound 4 when
pitched against Cl-amidine (Figure 4B,D). Notably, compound 6 was also able to significantly inhibit the
histone H3 citrullination. The compounds 2 and 3 were ineffective and resulted in the band intensity
comparable to the DMSO-treated control.
PAD4 is instrumental in the innate immunity system by the induction of NETs, the
neutrophil-derived DNA expulsion with antimicrobial and inflammatory properties. NETs release
was stimulated by the incubation of the peripheral blood-isolated neutrophils with PMA (phorbol
12-myristate 13-acetate) in the cells preincubated with the 30–100 µM compound 4, Cl-amidine or
DMSO as vehicle control. Expectedly, PMA incubation stimulated the neutrophils to release DNA
in the inhibitor-untreated cells and 30 µM Cl-amidine inhibited this effect. Compound 4 at 30 µM
displayed limited ability to block DNA release, while at the 100 µM, compound 4 was more effective
than Cl-amidine (Figure 5B). Furthermore, when NET release was visualized by DNA (blue) and a
specific NET marker, histone fragment H2A (red) immunostaining, only PMA-alone stimulated cells
were able to release fully developed NETs, while 100 µM Cl-amidine and compound 4 blocked the
NET formation (Figure 5A).
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from healthy blood donors were allowed to adhere to coverslips pre-coated with poly-L-lysine. They
were pre-incubated with DMSO alone, or with 100 µM of compound 4 or Cl-amidine and then
stimulated with PMA. Immunostaini g for hist ne H2 was performed with allophyco yani (APC)
F(ab’)2 goat anti-rabbit antibodies against histone H2A (red) with DNA counterstained with Hoechst
33258 (blue). Representative immunofluorescent images of 2 independ t experiments are shown.
(B)Human neutrophils isolated from healthy blood donors were allowed to adhere to a 24-wells plate
coated with poly-L-lysine. They were pre-incubated with DMSO alone, or with either 30 µM or
100 µM of compound 4 or Cl-amidine and then stimulated with PMA. Supernatants were collected and
quantification of extracellular DNA release was performed with the DNA-intercalating dye, Picogreen.
Results are expressed as mean ± SD, with n ≥ 3 and the differences were considered significant if
(*) p < 0.05 or (**) p ≤ 0.01. RFU—relative fluorescence units.
Taken together, the presented data indicate compound 4, a commercially-available molecule,
as the most effective inhibitor of GST-PAD4, potent in the in vitro biochemical assays as well in the
cell-based models of PAD activity. The effectiveness of the novel compound 4 was comparable or even
better than widely used Cl-amidin in all performed exper ments, suggesting the compound 4 as a
candidate for further development of PAD4-specific inhibitors of increased efficiency.
3. Discussion
Given PADs fundamental role in transcriptional regulation and aetiopathology of various
inflammatory diseases, plenty of research and development work has attended to develop efficient and
safe PAD inhibitors for clinical use [35]. In the present study, six novel compounds discovered using in
silico high-throughput screening approach; two of them commercially available and four proprietary
of 4SC AG; were assessed and compared to the well-established pan-PAD-inhibitor, Cl-amidine, for
potential inhibition of PAD4 and PPAD.
Apart from the human PADs, a growing body of evidence su ports a role for bacterial PAD in the
initiation and pathogenesis of RA [24], thus making P. gingivalis PPAD a viable arget f r development
of therapeutic inhibitors. The efforts to develop an efficie t PPAD inhibitor have b en unsuccessful so
far and similarly, the results of our study show that none of the candidate co pounds exerts activity
against PPAD. This is not surprising and likely reflects the significant differences between PAD4 and
PPAD in both structure and the mechanism of action. Indeed, PPAD and human PADs have a low
sequence homology [36] and distinct substrate specificities [37], confirmed herein by determination
of the Dansyl-Gly-Arg processing kinetics. Calculated Km, kcat and resulting kcat/Km values indicate
nearly 40× better processing of the Dansyl-Gly-Arg substrate by bacterial PPAD, mainly a result of
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the higher substrate affinity. Unlike its eukaryotic counterparts, PPAD preferentially citrullinates
C-terminal arginines of peptides [21] and acts in a calcium-independent manner [38]. This suggests
that the common inhibitor of both enzymes will be difficult to develop, at the same time indicating the
possibility that the future PPAD specific inhibitor will exhibit high selectivity and low side effects.
Our biochemical assays clearly indicate that four of the tested compounds (compound 2, 3, 4, and
6) were effective PAD4 inhibitors in the micromolar range. These compounds showed around 3–5-fold
increase in PAD4 inhibition when pitched against Cl-amidine (IC50 = about 1.28–1.88 µM, compared
to Cl-amidine with IC50 = about 5 µM) [33], signifying the improved effectiveness of the inhibition
and providing basics for the future targeted drug development and inhibitor design. Similarly, the
presented data indicate the importance of the host derived factors in the development of inhibitors
with potential therapeutic role. In experiments where serum of either healthy or patients with RA was
included in the sample preparation, the effectiveness of all inhibitors, including Cl-amidine, was clearly
impaired and the addition of RA synovial fluid nearly completely blocked the effect of all the inhibitors.
This deleterious effects of serum and synovial fluid on the compounds’ ability to act as PAD4 inhibitors
can be explained by their direct interactions with serum or synovial fluid components, e.g., binding to
other proteins and/or inactivation by other enzymes present in the milieu. Alternatively, serum and
synovial fluid might affect the activity of the PAD4 itself, or both effects could play a role. In RA, the
synovial joint inflammation is a hallmark of the disease and prominent accumulation of citrullinated
proteins and ACPAs is observed in the affected areas [39,40]. PAD4 is expressed in the synovial tissue
of patients with RA and is believed to play an essential role in the generation of synovial ACPA targets.
Therefore, targeting PAD4 in synovium is a valid strategy of protection from the autoimmune reaction
and the local interactions need to be included in the analysis of the inhibitor effectiveness.
Previous studies have correlated PAD4 expression with the histone citrullination [13,14] and
identified histone H3 as the preferred substrate for PAD4 [15,16]. As such, PAD4 has an essential role in
the chromatin decondensation and subsequent NET formation, thus contributing to the development
of many inflammatory-related diseases, including RA [12]. Therefore, the inhibitory effects of the
investigated molecules on histone H3 citrullination and NET formation were determined in the current
study. Purified histone H3 and cell culture data were compatible and identified compound 4 as a
novel inhibitor of PAD4-mediated histone H3 citrullination. Again, the citrullination of the histone H3
was inhibited more efficiently by compound 4 when compared to the Cl-amidine. In contrast, 30 µM
Cl-amidine was superior in the NET formation in vitro cell assay, in comparison to the compound 4 at
the same concentration. Nonetheless, both inhibitors were equally effective at 100 µM concentration
and the observed differences may be explained by the membrane permeability of the inhibitor, a
property likely to be optimized in the design process.
Selective PAD4 inhibitors have been described by Lewis and co-workers [14,41], allowing to
validate the critical role of PAD4 in both histone citrullination and neutrophil extracellular trap
formation. Therefore, the identification of isoenzyme-specific PAD inhibitors is desirable, given the
essential functions of the human PADs in normal physiology [2]. As our investigations were focused
on the selection of the kinetically best candidate compound in vitro and ex vivo, the selectivity of the
compounds was not evaluated.
An important consideration for the inhibitor analysis is the kinetic model of inhibition. In the
presented study we assumed a tight-binding competitive inhibition. This allows the Ki determination
and is a good approximation of both reversible and irreversible inhibitors, where the irreversible
inhibitor would be characterized by high kon, but koff equal (or close to) zero. Nonetheless, the
exosite binding and allosteric inhibition cannot be followed in this model and require further analysis.
In addition to Ki, we provide the measurement of IC50, as a universal parameter allowing the
model-independent comparison of the compounds under the same experimental conditions. Another
important consideration is the composition of the reaction buffer. Reducing agents, pH, and Ca2+ are
essential factors regulating the PAD4 activity [42] and indeed, the DTT concentration was critical for
the inhibitory effect of all compounds, including Cl-amidine. The in vitro assays were optimized to
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provide the correct inhibition for kinetic analysis and included 0.5 mM DDT in the reaction buffer,
however, this could not be controlled when patient samples were included. Therefore, the diminished
potential of the inhibitors in the serum and/or synovial fluid could be explained, at least partially, by
the decreased redox potential in the biological fluids, when compared to the reaction buffer alone.
Nonetheless, despite possible limitations, compound 4 was identified as an optimal inhibitor in all
assays, including the cell culture in vitro analysis.
In conclusion, herein we describe four novel PAD4 inhibitor compounds. All are characterized
by the micromolar-range inhibition potency against PAD4 in vitro. Similarly to Cl-amidine, they
demonstrated impaired efficacy in the presence of serum and synovial fluid from patients with RA.
Importantly, the best candidate (compound 4) outperformed Cl-amidine, the commonly used pan-PAD
inhibitor, in almost all assays and is freely available commercially. We believe that compound 4
presented here may serve as a design template for further optimization and will allow development
of specific inhibitors allowing the investigation of the biology of PAD4 and introduction of the new
strategies of RA treatment.
4. Materials and Methods
4.1. Compounds
Four proprietary compounds, protected by an NDA agreement, and two commercially available
molecules, as listed in Table 2, were kindly provided by 4SC AG (Planegg-Martinsried, Germany).
Compounds were selected by an in silico high-throughput screening approach as potential inhibitors
of peptidyl deiminase activity. The chemical structures of commercially available compounds 1 and
4 are presented in Figure 6. All compounds were dissolved in DMSO at 10 mM and stored as stock
solutions at −20 ◦C until used.
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Table 2. List of the tested compounds.
Compound 4SC Catalogue AvailableCommercially
Chemical
Structure Manufacturer Cat. No.
1 SC100288 Yes Yes Vitas-M Ltd. STK816131
2 SC100449 n.a. n.a. n.a. n.a.
3 SC101037 n.a. n.a. n.a. n.a.
4 SC97362 Yes Yes Labotest OHG LT02193089
5 SC99514 n.a. n.a. n.a. n.a.
6 SC101038 n.a. n.a. n.a. n.a.
Cl-amidine - Yes Yes Sigma-Aldrich 506282-10MG
Compounds were provided by 4SC AG and are identified with the 4SC ID numbers. Two of the molecules (1 and
4) are commercially available and their manufacturer and respective catalogue number is provided. Chemical
structures are available for these compounds. Cl-amidine was used as the standard PAD inhibitor for validation
purposes. n.a.—not available.
4.2. Patient Samples
Sera samples and synovial fluid were collected from patients with RA and healthy controls at the
Haukeland University Hospital in Bergen. The study was approved by the Regional Committee of
Medical and Health Research Ethics (REK 3.2006.3085) and all participants gave informed consent.
Neutrophils were isolated from peripheral venous blood samples, collected from voluntary blood
donors from the blood bank at the Haukeland University Hospital in Bergen (Norway), or the Red Cross
(Krakow, Poland) and was appropriately de-identified for human subjects confidentiality assurance.
Therefore, this study adheres to appropriate exclusions from human subjects approval and appropriate
state ethical regulations.
4.3. Reagents
GST-PAD4 was purified according to the modified protocol published elsewhere [43] with
required changes for purification of the GST-tagged proteins. Porphyromonas gingivalis HisTag-PPAD
was purified as described previously by Bielecka et al. [44]. Dansyl-Gly-Arg and Dansyl-Gly-Cit
peptides were custom-synthetized by Thinkpeptides (Oxford, UK). Purified histone H3, isolated from
calf thymus, was purchased from Roche Diagnostics (Mannheim, Germany) and dissolved in MilliQ
water. Cl-amidine was purchased from Calbiochem (Darmstadt, Germany) and dissolved in DMSO.
DMSO was used as vehicle control in each experiment.
4.4. Measurement of Enzyme Kinetics
The kinetic parameters of GST-PAD4 and HisTag-PPAD were assessed using Dansyl-Gly-Arg
as substrate, with concentrations ranging from 0.05 mM to 1 mM, and Dansyl-Gly-Cit as a product
standard. A total of 1 mU of each enzyme was used, which corresponds to the activity resulting in
the conversion of 1 nmol of arginine into citrulline within 1 h of the reaction. The assay was carried
out in 30 µL of assay buffer consisting of 100 mM Tris pH 7.5, 10 mM CaCl2 and 10 mM DTT at 37 ◦C
for 60 min, the reaction was terminated by adding 5% trichloroacetic acid (TCA) and incubated on
ice for 15 min. The samples were adjusted to 0.3% trifluoracetic acid (TFA) in 110 µL final volume,
centrifuged, and the supernatant was analyzed via HPLC (Shimadzu Corp., Kyoto, Japan). Separation
was achieved on an Aeris XB-C18 4.6/150 (Phenomenex, Torrance, CA, USA) reverse-phase column
in the gradient of Phase A (0.1% TFA in water) and Phase B (80% acetonitrile, 0.08% TFA in water).
Briefly, 20 µL of each sample was injected onto the column equilibrated in 10% of Phase B, the reaction
products were eluted in the separating gradient 10–30% of Phase B in 25 column volumes, under
the flow of 1.5 mL/min. Fluorescence emitted by dansyl (excitation at 342 nm, emission at 562 nm)
was monitored and the citrullination activity of PADs was calculated from the product peak area
of citrullinated Dansyl-Gly-Arg, relative to external calibration curves obtained with five different
concentrations of the Dansyl-Gly-Cit standard.
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4.5. Measurement of Inhibitor Constants and IC50
GST-PAD4 and HisTag-PPAD were pre-incubated for 30 min at 37 ◦C with DMSO alone or with
increasing concentrations (0.2–250 µM) of compounds 1 to 6 in the assay buffer (100 mM Tris pH 7.5,
10 mM CaCl2 and DTT). 1 mU of GST-PAD4 was used in the experiments. To optimize the concentration
of the reducing agent, experiments were done using different concentrations of DTT in the assay
buffer ranging from 0 to 10 mM and the final concentration for the presented results was 0.5 mM DTT.
Following pre-incubation of enzyme in the assay buffer, the reaction was initiated by the addition of
0.25 mM Dansyl-Gly-Arg. The reaction was stopped after 1h (as described above), the sample was
separated by HPLC and the relative activity of PAD in each sample was determined by measuring the
peak area of the citrullinated Dansyl-Gly-Arg.
4.6. Measurement of Inhibitory Activity in Serum and Synovial Fluid
A total of 50 µM of compounds 1 to 6 were pre-incubated with 1 mU of GST-PAD4 for 30 min at
37 ◦C with serum from healthy blood donors, serum or synovial fluid from patients with RA, serially
diluted from 1:1.5 to 1:30 in the assay buffer (100 mM Tris pH 7.5, 10 mM CaCl2). The reaction was then
initiated by the addition of 1 mM Dansyl-Gly-Arg and stopped after 1h as described above. The assay
included a negative and positive control: a DMSO (no compound) control and a known irreversible
compound (Cl-amidine) at 50 and 200 µM. Samples were separated by HPLC.
4.7. Histone H3 Citrullination Assay
A total of 50 µM of compounds 1 to 6 were pre-incubated with 1 mU of GST-PAD4 for 30 min
at 37 ◦C in the assay buffer (100 mM Tris pH 7.5, 10 mM CaCl2, 0.5 mM DTT). After that, 5 µg of
purified calf thymus histone H3 was added to the reaction mixture and incubated further for 60 min
at 37 ◦C. Three controls were performed in the assay: a DMSO (no compound) control and a known
irreversible compound (Cl-amidine) at 50 and 200 µM. The citrullination was assessed by western blot
using antibodies specific to citrullinated histone H3.
4.8. Histone H3 Citrullination in Neutrophils Stimulated with Calcium Ionophore
Neutrophils were isolated from human peripheral blood collected in acid citrate dextrose
(ACD-A) by first spinning blood on LymphoprepTM (Axis Shield, Oslo, Norway), followed by dextran
sedimentation using 3% dextran density gradient and hypotonic lysis of erythrocytes. Neutrophil
purity was assessed to be >90% by flow cytometry. Cells were resuspended at 2 × 106 cells/mL in
RPMI-1640 with HEPES (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 2 mM
CaCl2 and pre-treated for 30 min with DMSO alone, 50 µM of compounds 1 to 6 or with either
50 or 200 µM of Cl-amidine. Cells were then stimulated with 4 µM calcium ionophore A23187
(Sigma-Aldrich, St. Louis, MO, USA) or left unstimulated as controls for 15 min at 37 ◦C, 5% CO2.
Following stimulation, acid extraction of histones was performed according to Shechter et al. [45].
Briefly, cells were centrifuged (300× g, 10 min) and were resuspended in hypotonic lysis buffer (10 mM
Tris pH 8.0, 1 mM KCl, 1.5 mM MgCl2) supplemented with 1 mM DTT, 1 mM PMSF and complete
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) at a density of 2 × 106 cells/mL
then incubated on a rotator at 4 ◦C for 30 min. The nuclei were pelleted by spinning (10,000× g,
10 min, 4 ◦C), resuspended in 0.4 N H2SO4 and incubated on a rotator overnight at 4 ◦C. After spinning
(16,000× g, 10 min, 4 ◦C), supernatants were transferred to fresh tubes. TCA was then added drop by
drop to the histone solution (to the final concentration of 33%), after which the tubes were inverted
several times and incubated on ice for 30 min. Pelleted histones (16,000× g, 10 min, 4 ◦C) were washed
twice with ice cold acetone and air dried in for 20 min at room temperature. Histone pellets were
dissolved in MilliQ water (Merck Millipore, Burlington, VT, USA) and transferred into fresh tubes.
The presence of citrullination in cellular histones was analyzed by Western blot.
Int. J. Mol. Sci. 2019, 20, 2174 13 of 16
4.9. Western Blot
The protein concentration in each sample was measured (A280nm) and normalized post-extraction.
Next, histone proteins were separated in precast NovexTM 16% Tris-Glycine 1 mm minigels (Invitrogen,
Carlsbad, CA, USA). After electrophoresis, proteins were transferred into nitrocellulose membranes
(0.2 µm) at 4 ◦C (transfer buffer: 10 mM CAPS, 20% methanol, pH 11). Membranes were blocked for
1 h at room temperature with 5% milk in TBST (1× Tris Buffered Saline, pH 8.0, with 0.1% Tween 20)
and then incubated overnight at 4 ◦C with rabbit polyclonal anti-H3Cit antibody (Abcam, ab5103,
Cambridge, UK) at a 1:1,000 dilution in the blocking solution. All blots were probed with an HRP-linked
goat anti-rabbit secondary antibody (Abcam, ab205718) at a 1:10,000 dilution and then developed using
Clarity Western ECL substrate. The signal was recorded with ChemiDoc image analyzer (Bio-Rad
Laboratories, Hercules, CA, USA).
4.10. NET Assays
Granulocyte-enriched fractions were harvested using a lymphocyte separation medium density
gradient (PAN Biotech, Aidenbach, Germany). Neutrophils and erythrocytes were separated after
30 min of incubation with 1% polyvinyl alcohol (POCH, Gliwice, Poland). Neutrophils were collected
from the upper layer and after centrifugation (280× g, 10 min), the residual erythrocytes were removed
by lysis in water. Cells were then resuspended in serum-free DMEM without phenol red (Gibco,
Waltham, MA, USA). To measure the extracellular DNA release, neutrophils were seeded at 2 × 106/well
in 0.01 mg/mL poly-L-lysine (Sigma-Aldrich) coated 24-well plates and centrifuged (200× g, 5 min).
Neutrophils were treated for 1h with DMSO alone, or with either 30 µM or 100 µM of compound 4
or Cl-amidine. Cells were then stimulated with 25 nM PMA (phorbol 12-myristate 13-acetate) or left
unstimulated as controls for 3 h at 37 ◦C, 5% CO2. Following stimulation, the cell medium was collected
and the extracellular DNA was quantified using the Quant-iTTM PicoGreen® dsDNA Reagent (QPG;
Invitrogen, Carlsbad, CA, USA). The 1:200 dilution of QPG in TE buffer (10 mM Tris, 1 mM EDTA,
pH 7.5) and 90 µL of TE buffer was added to 10 µL of the supernatant containing the extracellular
DNA and fluorescence was measured with an excitation wavelength 480 nm and emission wavelength
520 nm.
For the NETs imaging assays, neutrophils were allowed to adhere to poly-L-lysine coated coverslips
(5 × 105 cells/coverslip) for 30 min at 37 ◦C, 5% CO2. Neutrophils were then treated for 1 h with
DMSO alone, or 100 µM of compound 4 or Cl-amidine. Neutrophils were then stimulated with 25 nM
PMA or left unstimulated as controls for 3 h at 37 ◦C, 5% CO2. Neutrophils were fixed with 3.7%
formaldehyde for 10 min, washed three times with PBS and blocked (5% FBS, 1% BSA, 0.05% Tween,
2 mM EDTA in PBS) for 1 h. Cells were washed and treated with 0.1% saponin (Sigma-Aldrich) in PBS
for 30 min. Cells were stained first with rabbit polyclonal anti-histone H2A antibody (Abcam), and
then with allophycocyanin (APC) F(ab’)2 goat anti-rabbit antibody (Jackson ImmunoResearch Lab Inc.,
Ely, UK) in the presence of 3% BSA in 0.1% saponin. Cells were counterstained with 1 µg/mL Hoechst
33258 dye (Invitrogen). Images were captured with a fluorescence microscope (Nikon Eclips Ti, Nikon,
Konan, Tokyo).
4.11. Statistical Analysis
The experiments have been performed at least three times and the results are presented as
means ± SD. One-way ANOVA with Dunnet’s post-test were used when comparing multiple groups.
The differences were considered significant if p ≤ 0.05.
The Michaelis constant (Km) was calculated by fitting a Michaelis plot of initial rate of enzymatic
product formation against the substrate concentration to the Michaelis–Menten equation using and
represent the mean ± SD from three different determinations.
The equilibrium inhibition constant (Ki) and IC50 were calculated from the fit of observed PAD
activity against the respective compound concentration. Data was analyzed by the built-in Morrisson
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equation for tight-binding inhibition [46] and represent the mean ± SD from at least three different
determinations. IC50 values were determined by the linear regression to the initial fragment of the
inhibition curve and are representative of inhibitor concentration required for the 50% reduction in the
product release during the reaction.
The statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software, La
Jolla, CA, USA).
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